GAiT is an international resource to facilitate the therapeutic use of immunogenetically matched, clinical-grade new types of stem cells (iPSCs) for the benefit of patients globally. GAiT’s vision is that patients globally will have equity of access to this new generation of iPSC-derived cell therapy products.
GAiT’s mission is to enable the global human community the opportunity to benefit from the new generation of cell therapies by facilitating the development of, and access to, clinical-grade and haplotyped induced pluripotent stem cells for the manufacture of cell therapy products.
- Achieve consensus on donor selection and screening criteria and consent standards.
- Achieve global consensus on manufacturing and quality parameters and standards required to consider an iPSC line to be of clinical grade and develop an external quality assurance scheme to facilitate the development of comparability between centres.
- Gain agreement with regulators in various jurisdictions as to the acceptability of the quality standards proposed.
- Develop a database of clinical grade iPSC lines.
News & Events
The latest from GAiT
GAiT Chairperson Prof Marc Turner will be speaking on GAiT activity in London 30th March - 1st April at the Terrapin 'Advanced Therapies Congress and Expo'
Research. Develop. Collaborate. Commercialise | Advanced Therapies
The global marketplace for investment, commercial opportunities and collaboration in the advanced therapies and regenerative medicine space.
A report released by the @CGTCatapult states that employment in the UK cell and gene therapy industry is set to double by 2024 the report indicates there are concerns over how demand will be met; primarily, the availability of targeted academic courses
Demand for ‘specialist skills’ in UK cell and gene therapy, says report
A skills demand report stated that employment in the UK cell and gene therapy industry is expected to double by 2024, with support of targeted courses...
GAiT will be speaking at the 'Translation and Innovation in induced Pluripotent Stem Cell Science' Workshop at Saïd Business School, Oxford on the 11th February 2020 and at the RESTORE meeting in Berlin on the 17th February 2020.
Osaka University transplants iPS cell-based heart cells in world's first clinical trial
Osaka University transplants iPS cell-based heart cells in world's first clinical trial | The Japan Times
An Osaka University team said it has carried out the world's first transplant of cardiac muscle cells created from iPS cells in a physician-initiated ...
Who would have thought 5 years ago that GSK, BMS, Gilead, Pfizer, Roche, J&J, Takeda, Astellas, Vertex... - will become the major cell-gene therapy companies? The craze for acquisitions will continue in 2020. Pharma/Biotech will eat them all!
Thanks to all who participated in the iPSC Quality Round Data Discussion calls this week! Minutes will be sent out Monday.
A Quality Round update was just sent to Participants. We remind those doing retests to upload the data template sheets in addition to raw data.
Tokyo's Heartseed reaps $26M to test its iPS cell injections for heart failure - The company forms spherical clusters of heart cells from purified, allogeneic iPSCs, which are injected into the heart muscle wall.
We are very grateful for @NIBSC_MHRA, @MCRI_for_kids, @yposkesi, @nyscf, @Inserm, and @cmrb for joining the first two Quality Round data discussion calls today. Your comments and feedback have been documented.